Build - not sure if you mentioned it in your summary that BK already exercised their right of first refusal on Australia and NZ. Additional funds on way next week for that. Also BK will be paying additional licensing fees for manufacturing (if I heard that correct) as the initial 2.625MM was only for technology.
I believe there was a third potential license fee but can’t remember what for. Anybody know?
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links